CARGO Therapeutics, Inc. is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. CARGO’s programs, platform technologies, and manufacturing strategy are designed to directly address the limitations of approved cell therapies, including limited durability of effect, safety concerns and unreliable supply. CARGO is currently evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor (CAR) T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. CARGO also plans to evaluate CRG-022 in patients at earlier stages of disease, including LBCL and other hematologic malignancies. Beyond its lead program, CARGO is leveraging its proprietary cell engineering platform technologies to develop a pipeline of programs that incorporate multiple transgene therapeutic “cargo” designed to enhance CAR T-cell persistence and trafficking to tumor lesions, as well as to help safeguard against tumor resistance and T-cell exhaustion. CARGO’s founders are pioneers and world-class experts in CAR T-cell therapy, and its team has significant experience and success developing, manufacturing, launching and commercializing oncology and cell therapy products. For more information, please visit the CARGO Therapeutics website at https://cargo-tx.com/.
Company profile
Ticker
CRGX
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
IRS number
844080422
CRGX stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
8-K
Departure of Directors or Certain Officers
15 Apr 24
S-8
Registration of securities for employees
21 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
21 Mar 24
8-K
Entry into a Material Definitive Agreement
8 Mar 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
CARGO Therapeutics Reports Business Updates and Third Quarter 2023 Results
13 Dec 23
10-Q
2023 Q3
Quarterly report
13 Dec 23
Latest ownership filings
4
Kapil Dhingra
17 Apr 24
3
Kapil Dhingra
17 Apr 24
4
Ginna Laport
4 Mar 24
4
Shishir Gadam
4 Mar 24
4
Anup Radhakrishnan
4 Mar 24
4
Gina Chapman
4 Mar 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G
Third Rock Ventures V, L.P.
14 Feb 24
SC 13G
JANUS HENDERSON GROUP PLC
14 Feb 24
SC 13G
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Cash on hand (at last report) | 60.34 mm | 60.34 mm | ||||
Cash burn (monthly) | 9.57 mm | (no burn) | ||||
Cash used (since last report) | 66.15 mm | n/a | ||||
Cash remaining | -5.80 mm | n/a | ||||
Runway (months of cash) | -0.6 | n/a |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Dhingra Kapil | Stock Option Common Stock | Grant | Acquire A | No | No | 19.89 | 49,265 | 979.88 k | 49,265 |
1 Mar 24 | Gina Chapman | Stock Option Common Stock | Grant | Acquire A | No | No | 25.07 | 400,000 | 10.03 mm | 400,000 |
1 Mar 24 | Shishir Gadam | Stock Option Common Stock | Grant | Acquire A | No | No | 25.07 | 100,000 | 2.51 mm | 100,000 |
1 Mar 24 | Anup Radhakrishnan | Stock Option Common Stock | Grant | Acquire A | No | No | 25.07 | 130,000 | 3.26 mm | 130,000 |
News
Cargo Therapeutics Q4 2023 GAAP EPS $(1.49) Misses $(1.44) Estimate
21 Mar 24
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
18 Mar 24
12 Health Care Stocks Moving In Monday's Intraday Session
18 Mar 24
Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday
15 Mar 24